Current phase 1/2 research for neovascular age-related macular degeneration

Current Opinion in Ophthalmology

Volumn 26, Issue 3, 2015, Pages 188-193

  Pecen, Paula E ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

antiangiogenesis; neovascular age related macular degeneration; phase 1 2 clinical trial

Indexed keywords

ABICIPAR PEGOL; AVA 101; CHIMERIC PROTEIN; DE 120; ESBA 1008; EYE DROPS; HL CON1; OHR 102; PAN 90806; PAZOPANIB; PF 582; REGORAFENIB; SFLT01; SONEPCIZUMAB; SQUALAMINE; UNCLASSIFIED DRUG; X 82; ANGIOGENESIS INHIBITOR; ANTIBODY CONJUGATE;

ADENO ASSOCIATED VIRUS 2; AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION; GENE THERAPY; HUMAN; LOW ENERGY RADIATION; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTON RADIATION; REVIEW; TREATMENT OUTCOME; PROTON THERAPY; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; GENETIC THERAPY; HUMANS; IMMUNOCONJUGATES; PROTON THERAPY; WET MACULAR DEGENERATION;

EID: 84926659796     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0000000000000147     Document Type: Review

References (32)

1. Ferris FL II. Senile macular degeneration: review of epidemiologic features. Am J Epidemiol 1983; 118:132-151.
2. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014; 2:e106-e116.
3. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102:1640-1642.
4. Levinson DR. Medicare payments for drugs used to treat wet age-related macular degeneration. Office of Inspector General. Department of Health and Human Services. April 2012. OEI-03-10-00360. (http://oig.hhs.gov/oei/ reports/oei-03-10-00360.pdf). [Accessed 11 January 2014]
5. Maclachlan TK, Lukason M, Collins M, et al. Preclinical safety evaluation of AAV2-sFLT01: a gene therapy for age-related macular degeneration. Mol Ther 2011; 19:326-334.
6. Heier JS. Preliminary results of phase 1 study with AAV2-sFLT01 as gene therapy for treatment of exudative AMD: one-year results of phase 1 clinical trial with rAAV.sFLT-1. The Retina Society 2014 Annual Meeting; September 12, 2014; Philadelphia, PA.
7. Heier, JS. Gene therapy for exudative AMD: one-year results of phase 1 clinical trial with rAAV.sFLT-1. American Society of Retinal Specialists 2014 Annual Meeting; August 12, 2014; San Diego, CA.
8. Binkley K, Widdsowson PS, Kelleher M, et al. Safety and biodistribution of an equine infectious anemia virus-based gene therapy, Retinostat1, for agerelated macular degeneration. Hum Gene Ther 2012; 23:980-991.
9. Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD) (GEM). https://clinicaltrials.gov/ct2/show/ study/NCT01301443?term=neovascular+age-related+macular+degenera tion%2C+treatment. [Accessed 11 January 2014]
10. Csaky KG, Dugel PU, Pierce AJ, et al. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology 2015; 122:579-588.
11. Clarke JM, Hurwitz HI, Rangwala F. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. Cancer Treat Rev 2014; 40:1065-1072.
12. Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration (DREAM). https://clinicaltrials.gov/ct2/ show/NCT02222207?term=neovascular+age-related+macular+degenera tion%2C+treatment&rank=43&submit-fld-opt. [Accessed 11 January 2014]
13. Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol 2008; 2:377-388.
14. Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects with Neovascular (Wet) Age-Related Macular Degeneration (AMD). https:// clinicaltrials.gov/ct2/show/NCT01678963?term=neovascular+age-related+ macular+degeneration%2C+treatment&rank=50&submit-fld-opt. [Accessed 11 January 2014]
15. PanOptica, Inc. http://www.panopticapharma.com/pan.html. [Accessed 11 January 2014]
16. Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD. https:// clinicaltrials.gov/ct2/show/NCT02022540?term=neovascular+age-related+ macular+degeneration+treatment&rank=224. [Accessed 11 January 2014]
17. Xie B, Shen J, Dong A, et al. Blockade of sphingospine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J Cell Physiol 2009; 218:192-198.
18. Efficacy and Safety Study of iSONEP With and Without Lucentis/Avastin/ Eylea to Treat Wet AMD (Nexus). https://clinicaltrials.gov/ct2/show/ NCT01414153. [Accessed 11 January 2014]
19. Brown DM. Oral anti-VEGF therapy for wet AMD. Paper presented at: Angiogenesis, Exudation, and Degeneration 2014; February 8, 2014; Miami, FL.
20. Pilot Study of X-82 in Patients With Wet AMD. https://clinicaltrials.gov/ct2/ show/NCT01674569?term=neovascular+age-related+macular+degenera tion+treatment&rank=138. [Accessed 11 January 2014]
21. Park SS, Daftari I, Phillips T, Morse LS. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration. Retina 2012; 32:956-966.
22. Prospective Randomized Trial of Proton Beam Combined with Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD) (PBAMD2). https://clinicaltrials.gov/ct2/show/NCT01213082?term=neovascular+agerelated+ macular+degeneration%2C+treatment&rank=69. [Accessed 11 January 2014]
23. Proton Radiation Therapy for Macular Degeneration. https://clinicaltrials.gov/ ct2/show/NCT01833325?term=neovascular+age-related+macular+degen eration%2C+treatment&rank=87. [Accessed 11 January 2014]
24. Jackson TL, Chakravarthy U, Slakter JS, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study. Ophthalmology 2015; 122:138-145.
25. Gonzales C. A phase 1 study targeting tissue factor with a single dose of intravitreal hl-con1TM for exudative age-related macular degeneration. American Academy of Ophthalmology: Retina Subspecialty Day. Nov 10, 2012; Chicago, IL. (http://www.iconictherapeutics.com/wp-content/uploads/2013/ 03/AAO-2012-Retina-Subspecialty-Day-Presentation.pdf). [Accessed 11 January 2014]
26. Souied EH, Devin F, Mauget-Faysse M, et al. Treatment of exudative agerelated macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol 2014; 158:724-732.
27. Stage 3 Phase 2 study of DARPin abicipar pegol (previously MP0112) supports progressing to phase II development. www.businesswire.com. July 1, 2014. http://www.businesswire.com/news/home/20140701005546/en/ Stage-3-Phase-2-study-DARPin-abicipar#.VJdsssAAA. [Accessed 11 January 2014]
28. Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration. https://clinicaltrials.gov/ct2/show/NCT02121353?term=neo vascular+age-related+macular+degeneration+treatment&rank=196. [Accessed 11 January 2014]
29. A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration. https://clinicaltrials.gov/ct2/show/NCT02022501? term=neovascular+age-related+macular+degeneration+treatment&rank= 201. [Accessed 11 January 2014]
30. Dugel PU. Results of ESBA 1008, a single-chain antibody fragment, for the treatment of neovascular AMD. American Society of Retina Specialists annual meeting. August 10, 2014; San Diego, CA.
31. ESBA1008 Microvolume Study. https://clinicaltrials.gov/ct2/show/ NCT01849692?term=neovascular+age-related+macular+degeneration+ treatment&rank=209. [Accessed 11 January 2014]
32. Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD. https://clinicaltrials.gov/ct2/show/ NCT02061865?term=neovascular+age-related+macular+degeneration+ treatment&rank=259. [Accessed 11 January 2014]